Despite no recent insider transactions for KKR Real Estate Finance Trust, the insider activities over the past year indicate a possible bullish sentiment. The insiders' stake indicates a reasonable alignment with the interest of the shareholders.
Long term performance of KKR Real Estate Trust is a worry for investors despite dividends. Overall shareholder return remains negative, signifying unresolved challenges.
Gainers: •$Okta(OKTA.US)$+15.8% (In reaction to earnings) •$StoneCo(STNE.US)$+12.9% (In reaction to earnings) •$Turning Point Therapeutics(TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$Amylyx Pharmaceuticals(AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
KKR Real Estate Finance Trust股票討論區
市盈率TTM爲虧損狀態,主要是信貸損失準備金暴增引起,市盈率53,按5年平均淨利0.74億計算,市盈率爲11.4,短期市盈率較高,暫時觀望。
• $Okta(OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
暫無評論